Maher, Toby - University College London

个人简介

Dr Maher qualified from Southampton Medical School. He trained in respiratory medicine at Royal Brompton Hospital, the Transplant Unit at Harefield Hospital and at St Mary?s Hospital, Paddington. During his training he gained an MSc in respiratory medicine from Imperial College London. In 2005 Dr Maher was awarded a Wellcome Trust Clinical Research Fellowship that enabled him to study the molecular mechanisms involved in the development of idiopathic pulmonary fibrosis. This research was undertaken at the Centre for Respiratory Research, University College London and culminated in the award of a PhD. Dr Toby Maher is consultant respiratory physician at the Royal Brompton Hospital, London. In addition to being an Honorary Senior Lecturer at UCL, he also holds the position of honorary senior lecturer at the National Heart and Lung Institute, Imperial College, London. Clinically, his particular areas of expertise include: idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis, sarcoidosis, Langerhan?s cell histiocytosis and Lymphangeiolyomyomatosis. He also manages pulmonary fibrosis and lung disease associated with systemic conditions such as Rheumatoid arthritis, Scleroderma and Wegener?s granulomatosis.

研究领域

Dr Maher?s specific research interests include; biomarker discovery, clinical trials in fibrosing lung disease and study of the role of prostanoids, apoptosis and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis (IPF). He is Chief Investigator of the PROFILE study (NCT01110694), a large scale prospective biomarker study in IPF and of TOPICAL-IPF (NCT01457261), a study of drug deposition in the lungs of individuals with IPF.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Journal article; 2017; Respir Res Links: IRIS | Author's | DOI Authors: Molyneaux PL,Cox MJ,Wells AU,Kim HC,Ji W,Cookson WO,Moffatt MF,Kim DS,Maher TM click to collapse Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Journal article; 2017; Thorax Links: IRIS | Author's | DOI Authors: Kreuter M,Bonella F,Maher TM,Costabel U,Spagnolo P,Weycker D,Kirchgaessler KU,Kolb M click to collapse Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis. Journal article; 2017; Am J Respir Crit Care Med Links: IRIS | Author's | DOI Authors: Molyneaux PL,Willis Owen SA,Cox MJ,James P,Cowman S,Loebinger M,Blanchard A,Edwards LM,Stock C,Daccord C,Renzoni EA,Wells AU,Moffatt MF,Cookson WO,Maher TM click to collapse Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. Journal article; 2017; Thorax Links: IRIS | Author's | DOI Authors: Alton EW,Beekman JM,Boyd AC,Brand J,Carlon MS,Connolly MM,Chan M,Conlon S,Davidson HE,Davies JC,Davies LA,Dekkers JF,Doherty A,Gea-Sorli S,Gill DR,Griesenbach U,Hasegawa M,Higgins TE,Hironaka T,Hyndman L,McLachlan G,Inoue M,Hyde SC,Innes JA,Maher TM,Moran C,Meng C,Paul-Smith MC,Pringle IA,Pytel KM,Rodriguez-Martinez A,Schmidt AC,Stevenson BJ,Sumner-Jones SG,Toshner R,Tsugumine S,Wasowicz MW,Zhu J click to collapse A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. Journal article; 2016; Pharmacoeconomics Links: IRIS | Author's | DOI Authors: Rinciog C,Watkins M,Chang S,Maher TM,LeReun C,Esser D,Diamantopoulos A click to collapse Acute exacerbation of idiopathic pulmonary fibrosis an international working group report Journal article; 2016; American Journal of Respiratory and Critical Care Medicine Links: IRIS | DOI Authors: Collard HR,Ryerson CJ,Corte TJ,Jenkins G,Kondoh Y,Lederer DJ,Lee JS,Maher TM,Wells AU,Antoniou KM,Behr J,Brown KK,Cottin V,Flaherty KR,Fukuoka J,Hansell DM,Johkoh T,Kaminski N,Kim DS,Kolb M,Lynch DA,Myers JL,Raghu G,Richeldi L,Taniguchi H,Martinez FJ click to collapse Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Journal article; 2016; The Lancet. Respiratory medicine Links: IRIS Authors: Kreuter M,Wuyts W,Renzoni E,Koschel D,Maher TM,Kolb M,Weycker D,Spagnolo P,Kirchgaessler KU,Herth FJ,Costabel U click to collapse Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution - Authors' reply. Journal article; 2016; The Lancet. Respiratory medicine Links: IRIS Authors: Kreuter M,Wuyts W,Renzoni E,Koschel D,Maher TM,Kolb M,Weycker D,Spagnolo P,Kirchgaessler KU,Herth FJ,Costabel U click to collapse Blood-based Diagnosis of Idiopathic Pulmonary Fibrosis. Fantasy or Reality? Journal article; 2016; Am J Respir Crit Care Med Links: IRIS | Author's | DOI Authors: Maher TM Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. Journal article; 2016; American journal of respiratory and critical care medicine Links: IRIS Authors: Russell AM,Adamali H,Molyneaux PL,Lukey PT,Marshall RP,Renzoni EA,Wells AU,Maher TM click to collapse Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis Journal article; 2016; CLINICAL SCIENCE Links: IRIS | UCL Discovery | Author's | DOI Authors: Evans IC,Barnes JL,Garner IM,Pearce DR,Maher TM,Xu S,Renzoni EA,Wells AU,Denton CP,Laurent GJ,Abraham DJ,McAnulty RJ click to collapse Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF Journal article; 2016; THORAX Links: IRIS | UCL Discovery | Author's | DOI Authors: Mercer PF,Woodcock HV,Eley JD,Plate M,Sulikowski MG,Durrenberger PF,Franklin L,Nanthakumar CB,Man Y,Genovese F,McAnulty RJ,Yang S,Maher TM,Nicholson AG,Blanchard AD,Marshall RP,Lukey PT,Chambers RC click to collapse Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia. Journal article; 2016; BMC genetics Links: IRIS Authors: Fingerlin TE,Zhang W,Yang IV,Ainsworth HC,Russell PH,Blumhagen RZ,Schwarz MI,Brown KK,Steele MP,Loyd JE,Cosgrove GP,Lynch DA,Groshong S,Collard HR,Wolters PJ,Bradford WZ,Kossen K,Seiwert SD,du Bois RM,Garcia CK,Devine MS,Gudmundsson G,Isaksson HJ,Kaminski N,Zhang Y,Gibson KF,Lancaster LH,Maher TM,Molyneaux PL,Wells AU,Moffatt MF,Selman M,Pardo A,Kim DS,Crapo JD,Make BJ,Regan EA,Walek DS,Daniel JJ,Kamatani Y,Zelenika D,Murphy E,Smith K,McKean D,Pedersen BS,Talbert J,Powers J,Markin CR,Beckman KB,Lathrop M,Freed B,Langefeld CD,Schwartz DA click to collapse Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Journal article; 2016; Thorax Links: IRIS Authors: Kolb M,Richeldi L,Behr J,Maher TM,Tang W,Stowasser S,Hallmann C,du Bois RM click to collapse Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predicted. Journal article; 2016; Respir Med Links: IRIS | Author's | DOI Authors: Ward K,Spurr L,Goldman NR,Margaritopoulos GA,Kokosi M,Renzoni E,Chua F,Maher TM,Ward S,Wells AU click to collapse Potential Role Of Altered Clusterin Expression And Localization In Ipf To Limit Fibroproliferation Conference presentation; 2016; Links: IRIS | UCL Discovery | Author's Authors: Peix L,Evans IC,Pearce DR,Simpson JK,Maher TM,McAnulty RJ click to collapse Precision medicine in idiopathic pulmonary fibrosis. Journal article; 2016; QJM : monthly journal of the Association of Physicians Links: IRIS Authors: Maher TM Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease? Journal article; 2016; Trends in molecular medicine Links: IRIS Authors: Byrne AJ,Maher TM,Lloyd CM click to collapse Rapamycin Insensitive Mtor Signalling Promotes Tgf-beta Induced Pro-Fibrotic Gene Expression In Human Lung Fibroblasts Conference ; 2016; AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Links: IRIS | Author's Authors: Woodcock H,Eley J,Peace S,Nanthakumar C,Maher TM,Mercer P,Chambers R click to collapse Recent advances in understanding idiopathic pulmonary fibrosis. Journal article; 2016; F1000Research Links: IRIS Authors: Daccord C,Maher TM click to collapse Reply: Daily Home Spirometry: A New Milestone in the Field of Pulmonary Fibrosis. Journal article; 2016; Am J Respir Crit Care Med Links: IRIS | Author's | DOI Authors: Russell AM,Maher TM,all authors click to collapse Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. Journal article; 2016; The European respiratory journal Links: IRIS Authors: Kreuter M,Wijsenbeek MS,Vasakova M,Spagnolo P,Kolb M,Costabel U,Weycker D,Kirchgaessler KU,Maher TM click to collapse Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. Journal article; 2016; Eur Respir J Links: IRIS | Author's | DOI Authors: Kreuter M,Wijsenbeek MS,Vasakova M,Spagnolo P,Kolb M,Costabel U,Weycker D,Kirchgaessler KU,Maher TM click to collapse Aerobic Glycolysis and the Warburg Effect. An Unexplored Realm in the Search for Fibrosis Therapies? Journal article; 2015; American journal of respiratory and critical care medicine Links: IRIS Authors: Maher TM Challenges in the classification of fibrotic ILD. Journal article; 2015; Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG Links: IRIS Authors: Bendstrup E,Maher TM,Manali ED,Wijsenbeek M click to collapse